by Raynovich Rod | Oct 7, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/15 1;20P… Both the IBB and XBI are stalled at the current 2020 double top. Our new picks are holding OSUR at $14.65, PACB $14.42 and VIR at $42. 10/16 11 a BioNTech (BNTX) and Pfizer emerging as vaccine leaders.Data coming soon. ==============...
by Raynovich Rod | Mar 2, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Feb 11, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Companies – Q1 2020 Update The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy ’15. FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected. Our Top...
by Raynovich Rod | Jan 21, 2020 | Biopharmaceuticals
Update-1 We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle. Markets are jittery despite rush to new highs at opening, S&P 500 down 0.82%, as of mid-day trading over...
by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
by Raynovich Rod | Nov 12, 2019 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2…One of the best days of the year for us; I will summarize later. Only laggard sector was speculative microcaps. Some of our best gains among healthcare/life science stocks: ABBV AMRN CRSP GILD ILMN TDOC UNH VCYT XBI ======= Update-1… Biotech gains...
by Raynovich Rod | Oct 15, 2019 | Biopharmaceuticals, Macro
Update-1 Large caps were mixed but our top picks are doing well: ABBV,BMY,MRK,RHHBY. But bad news from JNJ and BA may have curbed buyer’s sentiment. United Health (UNH) off Mondays lows of $220 to $245. In summary it looks like a good time fo adding larger cap...
by Raynovich Rod | Oct 2, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 10/4 Broad Rally day: all major averages up 1.4%, NAZ at 7982. Risk back on. But biotech lags major indices IBB up 0.75%, XBI up 0.21% to $76.82. Better trade for biotech has been large caps: ABBV, AMGN, MRK,RHHBY VRTX. Mid-cap movers: BLUE up 3.97%, GWPH up...
by Raynovich Rod | Sep 24, 2019 | Biopharmaceuticals, Macro
With biotech in a funk this timely article from Barron’s should help. Barron’s to the Rescue: Future of Biotech, article offers picks from a new Roundtable (above link may not open because requires subscription) Some of the picks ASND, MDCO,MGTX,NVTA,RGNX,...